Role of acetylcholinesterase inhibitors in pharmacological regulation of amyloid precursor protein processing

Aging Clinical and Experimental Research

Volumn 18, Issue 2, 2006, Pages 149-152

  Racchi, Marco ^a   Porrello, Emanuela ^a   Lanni, Cristina ^a   Lenzken, Silvia Carolina ^a   Mazzucchelli, Michela ^a   Govoni, Stefano ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Acetylcholinesterase inhibitors; Alzheimer's disease; A PP processing

Indexed keywords

3,4 DIAMINOPYRIDINE; AMBENONIUM; AMYLOID PRECURSOR PROTEIN; CHOLINESTERASE INHIBITOR; DICHLORVOS; DONEPEZIL; GALANTAMINE; GANSTIGMINE; HEPTYLPHYSOSTIGMINE; LADOSTIGIL; MESSENGER RNA; METRIFONATE; NEUROTRANSMITTER; PHENSERINE; PHYSOSTIGMINE; PHYSOSTIGMINE DERIVATIVE; RASAGILINE; RIVASTIGMINE; TACRINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CHOLINERGIC ACTIVITY; CHOLINERGIC SYSTEM; GENE EXPRESSION REGULATION; HUMAN; NERVE DEGENERATION; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN PROCESSING; QUALITATIVE ANALYSIS; REVIEW; SUBSTITUTION THERAPY;

EID: 33744807991     PISSN: 15940667     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03327431     Document Type: Review

References (13)

1. Kasa P, Rakonczay Z, Gulya K. The cholinergic system in Alzheimer's disease. Prog Neurobiol 1997; 52: 511-35.
2. Giacobini E. Long-term stabilizing effect of cholinesterase inhibitors in the therapy of Alzheimer' disease. J Neural Transm (Suppl) 2002; 62: 181-7.
3. Racchi M, Govoni S. The pharmacology of amyloid precursor protein processing. Exp Gerontol 2003; 38: 145-57.
4. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 1992; 258: 304-7.
5. Racchi M, Mazzucchelli M, Porrello E, Lanni C, Govoni S. Acetylcholinesterase inhibitors: novel activities of old molecules. Pharmacol Res 2004; 4: 441-51.
6. Lahiri DK, Farlow MR, Nurnberger JI Jr, Greig NH. Effects of cholinesterase inhibitors on the secretion of beta-amyloid precursor protein in cell cultures. Ann NY Acad Sci 1997; 826: 416-21.
7. Racchi M, Sironi M, Caprera A, Konig G, Govoni S. Short- and long-term effect of acetylcholinesterase inhibition on the expression and metabolism of the amyloid precursor protein. Mol Psychiatry 2001; 6: 520-8.
8. Mazzucchelli M, Porrello E, Villetti G, Pietra C, Govoni S, Racchi M. Characterization of the effect of ganstigmine (CHF2819) on amyloid precursor protein metabolism in SH-SY5Y neuroblastoma cells. J Neural Transm 2003; 110: 935-47.
9. Zimmermann M, Gardoni F, Marcello E, et al. Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines. J Neurochem 2004; 90: 1489-99.
10. Pakaski M, Rakonczay Z, Fakla I, Papp H, Kasa P. In vitro effects of metrifonate on neuronal amyloid precursor protein processing and protein kinase C level. Brain Res 2000; 863: 266-70.
11. Yogev-Falach M, Amit T, Bar-Am O, Weinstock M, Youdim MB. Involvement of MAP kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline. FASEB J 2002; 16: 1674-6.
12. Shaw KT, Utsuki T, Rogers J, et al. Phenserine regulates translation of beta-amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc Natl Acad Sci USA 2001; 98: 7605-10.
13. Lanni C, Mazzucchelli M, Porrello E, Govoni S, Racchi M. Differential involvement of protein kinase C alpha and epsilon in the regulated secretion of soluble amyloid precursor protein. Eur J Biochem 2004; 271: 3068-75.